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Abstract: Infectious agents, especially bacteria and viruses, account for a vast number of hospital-
isations and mortality worldwide. Providing effective and timely diagnostics for the multiplicity
of infectious diseases is challenging. Conventional diagnostic solutions, although technologically
advanced, are highly complex and often inaccessible in resource-limited settings. An alternative
strategy involves convenient rapid diagnostics which can be easily administered at the point-of-care
(POC) and at low cost without sacrificing reliability. Biosensors and other rapid POC diagnostic
tools which require biorecognition elements to precisely identify the causative pathogen are being
developed. The effectiveness of these devices is highly dependent on their biorecognition capabili-
ties. Naturally occurring biorecognition elements include antibodies, bacteriophages and enzymes.
Recently, modified molecules such as DNAzymes, peptide nucleic acids and molecules which suffer
a selective screening like aptamers and peptides are gaining interest for their biorecognition capabili-
ties and other advantages over purely natural ones, such as robustness and lower production costs.
Antimicrobials with a broad-spectrum activity against pathogens, such as antibiotics, are also used
in dual diagnostic and therapeutic strategies. Other successful pathogen identification strategies
use chemical ligands, molecularly imprinted polymers and Clustered Regularly Interspaced Short
Palindromic Repeats-associated nuclease. Herein, the latest developments regarding biorecogni-
tion elements and strategies to use them in the design of new biosensors for pathogens detection
are reviewed.
Keywords: biorecognition; diagnosis; biosensor; pathogens; aptamers; antibodies; peptides; enzymes;
DNAzymes; peptide nucleic acids
1. Introduction
Infectious diseases remain a significant global health concern and cause of mortality.
Lower-respiratory infections, diarrhoeal diseases and tuberculosis are currently among the
top ten global causes of mortality [1]. A worrying development that will greatly hamper
treatment and control of infectious diseases is the emergence of drug-resistant pathogens
in recent decades. Currently, at least 700,000 people around the world die each year due to
infections caused by drug-resistant organisms [2].
For centuries, clinical manifestations were the most common means to establish a di-
agnosis for many infections. Remarkably, this is still often the case today because diagnosis
of an infection can take several days before a result is delivered. The classical methods
for microbial identification are based on culture, which is a slow process providing low
sensitivity and has limited use in viral identification. Other traditional microbial diag-
nostics use microscopy and staining, and serological methods, such as hemagglutination
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assays. Although inexpensive and rapidly performed, these methods suffer from the
disadvantages associated with culturing [3,4]. More recently, standard molecular methods
have been adopted for microbial diagnosis, such as Polymerase chain reaction (PCR) and
Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-
TOF). These methods, although highly sensitive and relatively fast to perform, are complex
and require expensive sophisticated equipment with low portability, often making them
inaccessible [3].
To successfully manage infectious diseases in a clinical setting, a rapid diagnosis and
administration of targeted antimicrobial or antiviral therapy is crucial [5]. Because current
solutions can fail to quickly identify serious infections, they can prove fatal due to a delay
in treatment. Examples of such conditions include sepsis, a potentially life-threatening
condition [6], and Clostridium botulinum infection, which produces lethal neurotoxins that
can lead to rapid deterioration of a patient but is sometimes misdiagnosed as stroke or
other conditions. To improve diagnostic outcomes, the World Health Organization (WHO)
defined that the ideal diagnostic tests should be affordable, sensitive, specific, rapid,
equipment-free and delivered to those who need them [7]. Most conventional methods do
not meet all or most of these criteria. With the aim of meeting these criteria, point-of-care
(POC) diagnostics such as biosensors for mass application are under development because
they are inherently flexible, easy to use, minimally instrumented and can be produced at
low costs [8].
Biorecognition elements, also referred to as bioreceptors, have the essential function
of providing analyte specificity to a biosensor. An ideal biorecognition element possesses a
selective and potent affinity towards the bioanalyte, thus endowing a biosensor with good
specificity [9]. This review provides an update on the different types of biorecognition
elements being studied and the strategies employed for the identification of pathogens
that can be used for POC diagnostics. Although the use of antibodies for biorecognition
dominates the landscape due to their inherent abilities for antigen detection, there are
a few challenges associated with their use in biosensors, such as instability and high
cost. Hence, recent research has been more focused on nucleic acid derivatives such as
aptamers and peptide nucleic acids (PNAs), which can be modified to improve their
biorecognition capabilities while being arguably more stable than antibodies. Numerous
studies have been conducted on aptamers and the most recent ones are herein summarised.
In addition, theranostic approaches which combine therapy and diagnosis [10] make use
of the dual properties of antibiotics and certain types of peptides to selectively detect
and simultaneously inactivate pathogens, making them extremely useful, and several
examples are discussed. Enzymes, similarly to antibodies, have intrinsic properties for
pathogen identification and have also been adapted to some extent, although they also
suffer from instability. Other recent strategies for pathogen identification are also explored,
such as Clustered regularly interspaced short palindromic repeats/associated nuclease
(CRISPR-Cas) and molecularly imprinted polymers (MIPs).
This plethora of promising biorecognition elements are versatile enough to be used by
themselves, routinely coated onto magnetic nanoparticles (MNPs), microparticles and mi-
crofluidic devices or included in detection probes where they are integrated into biosensors
for pathogen identification. All these strategies and methods are thoroughly discussed in
this review with a focus on sensing platforms used especially in POC diagnostics. Although
most of the reviews related to biosensors are more focused on the detection strategies and
principles [11,12], our review addresses the important aspect of how exactly the pathogenic
targets are identified or recognised prior to detection. In addition, a number of examples of
commercially available biosensors are examined. This aspect is often overlooked in other
reviews, which usually only consider results from research outputs.
2. Recent Progress in Platforms for Pathogen Detection
In the past few decades, biosensors have emerged as an alternative to conventional
diagnostic methods. Biosensors are highly advantageous due to their high sensitivity,
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low-cost, ease-of-use and rapid response time for analyte detection [12]. A biosensor
comprises a biorecognition element that binds to a target analyte (e.g. bacteria, virus,
protein, polysaccharide) and transducer elements that translate the binding occurrence
into a detectable signal with a detector providing readout (Figure 1) [13]. The translation
of prototype biosensors to commercial development has hitherto been a slow process.
However, in response to the emerging need for POC diagnostics and the manifold benefits
of sensor-based testing, numerous new commercial biosensors are being introduced to
worldwide markets.
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Figure 1. Main components of a biosensor: analyte, biorecognition element and transducer which
produces a detectable signal. The major types of biorecognition ele ents and analytes in the context of
clinical pathogen detection are included. PNAs: peptide nucleic acids. Created with BioRender.com.
Table 1 highlights some sensor-based products for the identification of pathogens that
are currently available on the market. Most of these pr ducts are based immunological
principles usi g antibodies to recognise the analyte. These commercial sensor platforms
are usually in the form of lateral flow immunoassays (LFA), latex agglutination assays and
rapid antigen tests. Other classes of novel biorecognition ele ents that have shown some
promise in pathogen identification are still not commonly used in commercial sensors.
Regarding the detection systems, biosensors based on electrochemical, piezoelectric and
optical principles are still not widely commercialised.
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Table 1. Commercially available clinical biosensors for identification of human pathogens.
Pathogen Class Biorecognition Element Company Product Type of Test Refs.
Clostridium difficile
Antibodies specific to C. difficile antigen
glutamate dehydrogenase Corisbio Clostridium K-SeT Immunochromatographic assay [14]
N/A Thermo Scientific Oxoid™ Clostridium difficile Test Kit Rapid latex agglutination [15]
Escherichia coli serogroup O157 N/A Meridian Bioscience, USA ImmunoCard STAT! E. coli O157 Plus Lateral flow immunoassay [16]
Antibodies specific to O157
serogroup antigen Thermo Scientific Escherichia coli O157 Latex Test Colorimetric latex agglutination [17]
Haemophilus influenzae b Antibodies specific to H. influenzaetype b antigen Thermo Scientific Wellcogen™ Haemophilus influenzae b Rapid Latex Agglutination [18]
Helicobacter pylori
Antibodies specific to H. pylori Quidel, USA QuickVue H. pylori Test Solid phase immunoassay [19]
Anti-H. pylori lgG antibody Beckman Coulter, USA Icon HP Immunoassay [20]
Antibodies specific to H. pylori antigens Corisbio Pylori-Strip/Pylori K-SeT Immunochromatographic assay [21,22]
Moraxella catarrhalis Indoxyl butyrate detects the enzymebutyrate esterase of M. catarrhalis Thermo Scientific Remel™ Catarrhalis Test Disc
Colorimetric chemical
identification [23]
Staphylococcus aureus A protein detects clumping factor andprotein A of S. aureus Thermo Scientific BactiStaph™ Latex Agglutination Test Kit
Agglutination of protein-coated
latex particles [24]
Streptococcus pneumoniae Specific rabbit antibody Thermo Scientific DrySpot™ Pneumo Latex Agglutination Test
Agglutination of antibody-coated
latex particles [25]
N/A Abbott BinaxNOW™ Streptococcus pneumoniaeAntigen Card Lateral flow immunoassay [26]
Epstein-Barr virus Heterophile antibody detects bovine redcell mononucleosis antigen Thermo Scientific
Infectious Mononucleosis Test using
Latex Agglutination Latex Agglutination [27]
Influenza A and B virus
Antibodies specific to Influenza type A
and type B antigens Quidel, USA QuickVue Influenza A + B test Immunoassay [28]




N/A Lucira Health COVID-19 All-In-One Test Kit (FDA approved) Amplification of viral geneticmaterial [30]
Antibody Abbott BinaxNOW COVID-19 Ag Card Home Test(FDA Emergency Use Authorization) Rapid antigen [31]
Antibody Ellume Health Ellume COVID-19 Home Test (FDA EmergencyUse Authorization) Rapid antigen [32]
Plasmodium falciparum
Antibodies detect histidine-rich protein II
antigen specific to P. falciparum and a
pan-malarial antigen
Abbott BinaxNOW® Malaria Immunochromatographic assay [33]
N/A—Information Not Available.
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Other advancements to improve diagnostics for infectious diseases make use of com-
putational methods and tools. More recently, computational modelling has been used to
design biorecognition elements with an effectiveness unlikely to be matched by conven-
tional wet laboratory techniques. Molecular docking is an example of a computational
modelling technique that has been used to design high-affinity biorecognition elements
towards the detection of pathogenic targets [34]. For ligand discovery, in silico simula-
tions have been used to design “superselective” multivalent probes by optimising the
multiplicity (binding to the target DNA at multiple sites), instead of the strength of the
probe-target bond, wherein the target can be pathogens, to enhance detection sensitivity
and specificity [35]. Technologies such as Next-Generation Sequencing (NGS) or massively
parallel sequencing, which are high throughput sequencing methods, have the potential to
establish hypothesis-free diagnostic approaches to detect virtually any pathogen leading to
a paradigm shift in how infections can be diagnosed [3]. Metagenomic NGS (mNGS) has
proven capabilities of detecting a wide range of pathogens present in a patient sample [36].
Additionally, the enrichment of target nucleic acids prior to mNGS enhances the sensitivity
of detection [37]. To illustrate, Wylie and collaborators [38] developed a capture probe
called ViroCap, constituted by a panel of 2 million sequences able to enrich viral nucleic
acids of a large set of eukaryotic viruses preceding mNGS to increase the sensitivity of
virus detection. All the expected viruses from 26 clinical samples and 30 additional viruses
were detected, whereas when only mNGS was used some of the viruses were not detected.
Although mNGS can be successfully implemented, it is time- and resource-intensive and
requires bioinformatics expertise. Therefore, its potential in diagnostics is based on specific
cases where unsuspected or unculturable organisms are present and may be not detected
(false negative results) with standard assays.
3. Biorecognition Elements
The essential requirement of an effective biorecognition element is to provide speci-
ficity for the (bio)analyte (also referred to as the target) [9]. The most important charac-
teristics of a biorecognition element for pathogen identification are sensitivity (few false
negatives) and selectivity (few false positives) [39]. Widely used as biorecognition elements
are the antibodies’ immunoglobulins (Ig) due to their exceptionally high affinity and speci-
ficity towards their target analytes. Moreover, aptamers, peptides, bacteriophages and
enzymes, among others, have also been established as being effective for biorecognition
purposes. The targets of biorecognition elements, which enable pathogen identification,
are usually specific surface molecules (e.g., biomarkers), such as proteins and epitopes or
their by-products (toxins and metabolites) or nucleic acids. Exploring the various biorecog-
nition elements and their inherent characteristics is essential to improve and develop novel
POC diagnostics.
3.1. Antibodies
Igs, generally referred to as antibodies, are large glycoproteins produced by white
blood cells with strong affinity and specificity towards their target analytes. These qualities
make them a natural and popular choice as biorecognition elements and consequently, have
been adapted for use in pathogen identification. In addition to whole monoclonal antibod-
ies (mAbs), which are laboratory made, antibody-derived single-chain variable fragments
(scFv) and fragment antigen-binding (Fab’) units are commonly used for biorecognition [40].
They are more cost-effective than mAbs while providing similar specificity values as con-
ventional antibody approaches. Antibody-based probes are most commonly used for the
detection of specific proteins and whole cells [41]. Because numerous methods of pathogen
identification using antibodies as biorecognition elements have been reported, this review
provides only a brief overview of a few recent reported strategies.
Antibodies are identified within the relevant biochemical pathways and then produced
in animals and purified for various applications, including for use as capture probes
in sensors platforms [9]. Most examples of antibody-based biosensors for detection of
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pathogens use commercially produced antibodies, as in the case of Park et al. [42] who
developed a 3D printed microfluidic device with antibodies conjugated to MNPs (Ab-
MNPs) as capture probes against the common pathogen enterohaemorrhagic Escherichia
coli O157:H7. The device, termed a magnetic pre-concentrator (3DµFMP) was tested using
human blood mixed with 102–107 colony forming units (CFU) of E. coli O157:H7 and
Ab-MNPs (1013 particles/mL). The mixture was treated with adenosine triphosphate (ATP)
eliminating reagent before being injected into the 3DµFMP device. Captured cells were
then magnetically separated and quantified using an ATP luminescence assay achieving
an excellent limit of detection (LOD) of 10 CFU/mL in blood. The 3DµFMP device was
efficient, selectively enriching E. coli O157:H7 700-fold in a volume of 100 mL in one hour.
Antibodies were also used in multiplex detection of pathogenic bacteria by Jang et al. [43].
Figure 2 illustrates the synthesis of modified capture magnetic beads (MBs) and dual
nanoprobes for detection, which are based on both surface-enhanced Raman spectroscopy
(SERS) and fluorescence. Two different mAbs that recognise two pathogens, E. coli J5
and Francisella tularensis, were conjugated to respective MB-clusters for selective magnetic
capture (Figure 2A). The dual nanoprobes used for detection (Figure 2B,C), comprised
silver nanoparticles (AgNPs) conjugated with SERS reporters and fluorescence dyes and,
subsequently, the AgNP clusters were encapsulated. They were conjugated to another
pair of mAbs that recognise the respective bacterial targets (Figure 2A). In the presence
of F. tularensis and E. coli J5, the MBs-clusters selectively bind to the respective bacterial
target (Figure 2D). Following magnetic enrichment, the dual nanoprobes were added,
which formed sandwich-type immunocomplexes containing the bacteria, MB-clusters
and the dual nanoprobes (Figure 2E). Detection was performed by SERS (Figure 2F) and
fluorescence microscopy. A linear correlation was verified between the Raman intensity
and the pathogen concentration from 102 to 106 cells/mL, and the LOD was found to be
less than 102 cells/mL.
Another similar example adapted the use of antibody conjugated NP enrichment with
SERS detection in an easy-to-use LFA format. Primary antibody-conjugated magnetic gold
nanoparticles (AuNPs) were used for enrichment of E. coli. The enzyme rennet was used
to prevent aggregation of the AuNPs, to facilitate free movement of the bacteria along
the paper-based LFA strip followed by SERS detection. The sensitivity of this system was
comparable with a plate-counting method and could be completed in 1 h [44].
A POC biosensor for the identification of Mycobacterium tuberculosis was reported using
monoclonal antibodies with high specificity towards the well-established M. tuberculosis
heat shock protein X (HspX) [45]. The antibodies were directly immobilised on a plasmonic
sensor surface for detection, achieving a LOD of 0.63 ng/mL in pretreated sputum samples.
Using a similar strategy, Zika virus was detected by immobilising a monoclonal antibody
specific to an envelope protein of Zika virus onto an impedimetric immunosensor [46]. The
sensor achieved a low LOD of 10 picomolar.
Although antibodies have been the gold standard as affinity molecules for decades,
their limitations include poor stability and reproducibility, which complicate their use
in sensing platforms that require a long shelf-life. Other problems relate to lengthy pro-
duction time and the need for ethical approval, which increase costs [47]. Therefore,
research in recent years has also focused on finding alternate biorecognition elements with
improved specifications.
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3.2. Enzymes
Enzymes are natural, biologically derived molecules that have evolved an innate
ability to achieve analyte specificity [9]. Enzymes attain specificity to a bioanalyte through
binding cavities deep in their structure. Binding can occur by various means such as
hydrogen-bonding, electrostatic binding and other non-covalent interactions [48]. How-
ever, enzymes, such as antibodies, are sensitive to degradation, which affects their repro-
ducibility and, by extension, their applicability in biosensors. Liu et al. [49] developed
a microwave-assisted method for the synthesis of red fluorescence gold nanoclusters
(AuNCs) functionalised with lysozyme and demonstrated their potential use in a visual
detection nanosensor of E. coli. Lysozyme is advantageous as it reduces Au+ ions and
thus stabilises the AuNCs. Additionally, lysozymes are antimicrobial enzymes that can
recognise and kill several types of bacteria [50]. Due to lysozyme’s high specificity for E. coli
and the fluorescence enhancement of the lysozyme functionalised AuNCs, the nanosensor
detected E. coli with good sensitivity (LOD = 2 × 104 CFU/mL). Due to the nature of
the fluorescence evolution, the nanosensor can be suitably applied to real-time and fast
detection of bacteria.
Label-free and real-time genus-specific detection of bacterial pathogens using lytic
enzymes was proposed by Couniot et al. [51]. The lytic enzyme lysostaphin selectively
digests staphylococci. Therefore, a compatible microelectrode sensor with Staphylococcus
epidermidis anchored to its surface was incubated with lysostaphin. A real-time shift in
impedance was observed when target bacteria were lysed by the enzyme. The LOD
was calculated as 108 CFU/mL within a minute of bacterial incubation. Specificity of
the lysostaphin-based sensor to S. epidermidis was demonstrated in synthetic urine also
containing Enterococcus faecium.
More recently, Clemente et al. [52] proposed a simple visualised method for rapid
diagnosis of the respiratory pathogen Pseudomonas aeruginosa due to enzymatic liquefaction
of infected sputum samples. The catalytic conversion of hydrogen peroxide, when added
to an infected sample, by the P. aeruginosa enzyme catalase results in disruption of biofilms
and generates an effervescence of oxygen bubbles which can be clearly seen. Catalase is
produced only by P. aeruginosa and so other bacteria do not produce a reaction on addition
of hydrogen peroxidase. An LOD of 105 cells/mL was reported, which is considered the
clinical threshold for respiratory infections detection. An important advantage of using
enzymes instead of affinity molecules is that non-specific binding on sensors is eliminated,
which could greatly facilitate its use for real samples. Moreover, lytic enzymes can be
potentially applied in the detection of all Gram-positive bacteria.
3.3. Peptides
Peptides typically consist of short chains of 10–40 residues [53]. Antimicrobial peptides
(AMPs) are part of the innate immune system in many eukaryotes. They usually bind
to the negatively charged cell membranes of bacteria prompting cell lysis. AMPs have
been successfully applied as biorecognition elements, in part due to their broad-spectrum
activity against a variety of pathogenic bacteria. Cell-penetrating peptides (CPPs) are
another class of short peptide sequences that find application as biomolecular delivery
vehicles due to their ability to breach cellular membranes [54]. Both AMPs and CPPs have
potential as biosensors and therapeutics due to their ability to inactivate pathogens [55].
Synthetic peptides can be selected randomly by phage display from phage libraries for
application in biosensors and often perform better than antibodies [53,54]. Their relatively
easy synthesis and intrinsic stability render them as suitable candidates to increase the
shelf-life of sensor diagnostic platforms [56]. However, some key challenges are related to
detection of bacteria in real samples, and their relatively low sensitivity and selectivity for
diagnostic applications remain [53,57].
Certain pathogens can be identified indirectly based on their distinct by-products.
For example, E. coli and some other bacterial species produce high levels of alkaline phos-
phatase (ALP). Zhang et al. [58] constructed a fluorescent probe that senses bacterial ALP
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activity. The novel probe comprised a controlled aggregation-induced emission luminogen
(AIEgen) conjugated with a self-assembling peptide. The AIEgen-peptide probe designated
as TPEPy-DFDFPYDEGDK (TPEPy-pY) was designed containing a phosphorylated tyrosine,
which, in the presence of bacterial ALP, is dephosphorylated. The dephosphorylation of
TPEPy-pY reduces its hydrophilicity, causing the probe to assemble on the bacterial surface,
triggering the AIEgen to fluoresce. The probe demonstrated good sensitivity and selectivity
for ALP activity, with an LOD of 3.38 × 106 CFU/mL.
Numerous examples of biorecognition methods make use of AMPs. In a recent study,
Yuan et al. [59], reported MNPs modified with an AMP bacitracin A were able to capture
bacteria. Their work revealed that the interactions between bacitracin A and bacteria are
due to a pyrophosphate group present in the lipid target on bacteria and other indirect
interactions mediated by sodium and zinc ions. After magnetic separation, SERS tags
bound to the captured bacteria were used for their detection. The SERS spectra allowed to
distinguish between E. coli, Staphylococcus aureus and P. aeruginosa.
Seminal work related to AMPs employed Magainin I to semi-selectively identify
pathogenic bacteria [56]. Magainin I (GIGKFLHSAGKFGKAFVGEIMKS), which is nat-
urally present on the skin of African clawed frogs, exhibits antibiotic activity against
numerous species of bacteria. A micro-capacitive electrode sensor was functionalised
with Magainin I. The sensor demonstrated adequate selectivity to distinguish strains of
specific pathogenic Gram-negative bacteria, while Magainin I retained broadband detection
abilities. A sensitivity to E. coli of 1 bacterium/µL was achieved. Another enrichment and
detection platform comprised of a chemically modified microfluidic platform immobilised
with Magainin I to capture bacteria achieved an LOD of 5 CFU/mL of Salmonella and
10 CFU/mL of Brucella from urine samples within 60 min [60].
Class IIa bacteriocin AMPs such as leucocin A are noted for their anti-Listeria activity.
A study by Azmi et al. [61] highlights these attributes of leucocin A. A peptide array was
used to screen short peptides from a synthetic peptide library with selectivity for Listeria
monocytogenes for use as biorecognition elements in a sensor. By employing this screening
method, the Leucocin A fragment Leu10 (GEAFSAGVHRLANG) exhibited the highest
affinity to target bacteria relative to the other peptide fragments. Similarly, leucocin A
was used to selectively capture L. monocytogenes from among other Gram-positive strains
followed by impedimetric detection, as illustrated in Figure 3. An LOD of 103 CFU/mL
was achieved by this method [62].
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Figure 3. Graphical representation of an antimicrobial peptide (AMP)-based biosensor used for
impedimetric detection of bacteria. The AMP is i obilised on a icroelectrode array. The
functionalised sensor selectively captures the target cells due to the immobilised AMP. Created
with BioRender.com.
In some cases AMPs perform better than antibodies, as illustrated by Arcidiacono
et al. [63], who evaluated the potential of fluorescently labelled AMPs as an alternative to
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labelled antibodies in the detection of E. coli O157:H7. AMPs cecropin P1, SMAP29 and
PGQ were labelled with a fluorescent dye Cy5 and screened using a cell binding assay. It
was revealed that Cy5-cecropin P1 improved the detection of target bacteria 10-fold when
compared to a Cy5 labelled with an anti-E. coli O157:H7 antibody.
Other miscellaneous AMPs that have been researched for their biorecognition ca-
pabilities include Clavanin A and Ubiquicidin. Clavanin A is isolated from the marine
tunicate Styela clava. An electrochemical biosensor was constructed using AuNPs chem-
ically modified with cysteine and functionalised with Clavanin A for the detection of
Salmonella typhimurium and E. coli. The sensor displayed moderate sensitivity and was able
to differentiate signals for bacterial concentrations between 101 and 104 CFU/mL [64]. In a
different study, a chemically modified version of Ubiquicidin enhanced with a fluorophore
for detection by optical endomicroscopy demonstrated selectivity for pathogenic bacteria,
and for the pathogenic fungus Aspergillus fumigatus (that causes pulmonary infections) over
human cells in an ex vivo human lung model [65].
Multiplex systems based on arrays of various AMPs can be used for biorecognition of
various analytes such as viruses. Fluorescently labelled viruses can be identified based on
their characteristic response pattern upon interaction with the AMP panel [66]. Similarly,
the goal of a study conducted by Kulagina et al. [67] was to establish such a multiplex
detection system for pathogenic bacteria and viruses relevant to biodefence. The authors
developed an array of different types of AMPs immobilised on a sensing substrate. The
pathogens were fluorescently labelled and their identification was based on an evaluation
of their binding pattern to the immobilised AMPs. The pathogens tested were Venezuelan
equine encephalitis virus (VEE), vaccinia virus, Brucella melitensis and Coxiella burnetii.
The AMPs array comprised polymyxins B and E, cecropins A, B, and P, melittin, parasin,
bactenecin and Magainin I, and antibodies were used as controls. After the binding assays,
it was observed that most of the immobilised AMPs bound labelled vaccinia virus, VEE
and C. burnetii proportional to their concentration, and B. melitensis bound to bactenecin,
polymyxin B and E. By establishing the characteristic binding patterns of various microbial
pathogens, AMP arrays can be used to distinguish between them.
In a recent example, Fu et al. [68], developed a sensor array comprised of fluorogenic
peptide probes for the differential sensing of the Ebola virus (EBV). The probes were con-
structed based on self-assembly between graphene oxide, which is a strong fluorescence
quencher, and three fluorescently labelled peptide fragments T-RS5, T-QY7 and T-ED17,
which were derived from antibodies. In the presence of pseudo-viruses (not able to repli-
cate), the probes displayed an increase in fluorescence proportional to virus concentrations.
This suggests that the peptide probes are removed from the graphene oxide surface to form
peptide-virus complexes, resulting in fluorescence recovery. Based on the analysis of the
fluorescence signals, differential sensing is evident in spite of the similarity of the viral
capsid glycoproteins of EBV, Marburg virus and vesicular stomatitis virus.
A peptide microarray approach has also been developed to improve the accuracy of
COVID-19 diagnosis. For example, Li et al. [69] prepared a microarray of spike protein
(S1)-derived peptides from SARS-CoV-2 with full S1 coverage and analysed the immuno-
logical response from 2434 serum samples of COVID-19 patients including asymptotic
patients. Based on the results, several 12-mer peptides were identified as suitable antigens
to detect antibodies against SARS-CoV-2. While monitoring the IgG response, one of the
peptides exhibited a sensitivity of 95.5% and specificity of 96.7%, which is comparable to
the performance of the S1 itself for detection of symptomatic and asymptomatic COVID-19
cases. Additionally, a panel of four selected peptides was constructed with capabilities
to prevent potential cross-reactivity with serum containing other coronaviruses. Addi-
tionally, Cai et al. [70] also evaluated a serological method for COVID-19 diagnosis and
developed a peptide-based magnetic chemiluminescence enzyme immunoassay (MCLIA).
Twenty candidate peptide epitopes of antigens of SARS-CoV-2 were predicted in silico and
synthesised. The peptides were then linked to MBs and tested in an MCLIA with serum
from COVID-19 patients to detect their binding to IgG and IgM antibodies. A peptide
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derived from the S1 protein of the virus showed the best performance and was further
evaluated in an MCLIA with serum from 276 patients with COVID-19. The IgG and IgM
positive detection rates were found to be 71.4% and 57.2%, respectively. By comparison,
Pomplun et al. [71] screened peptides with high affinity towards the receptor-binding
domain (RBD) of SARS-CoV-2 S1 towards the development of an efficient SARS-CoV-2
diagnostics. A method based on affinity selection using mass spectrometry (MS) was used
to rapidly screen a library composed of 800 million synthetic peptides. Three sequences
were identified with dissociation constants in the range 80–970 nM for the RBD. It was
also shown that the RBD was selectively enriched by the selected peptides from a complex
matrix comprising human serum proteins.
Because numerous peptides have been successfully tested for their biorecognition
capabilities in sensing platforms and in arrays, they are promising candidates for use in
biosensors, especially when taken together with their various other stated benefits.
3.4. Nucleic Acid Derivatives
The development of in vitro selection methodologies, such as the so-called “Systematic
evolution of ligands by EXponential enrichment” (SELEX), to screen for single stranded
DNA or RNA (ssDNA or ssRNA) from random-sequence nucleic acid libraries with high-
affinity binding properties gave rise to intensive investigation on synthetic nucleic acids
with special properties [72]. Since then, a variety of functional synthetic nucleic acids and
their analogues have been developed for various diagnostics and therapeutic applications,
including aptamers, DNAzymes and PNAs [73,74]. These synthetic molecules have distinct
advantages over traditional antibodies as they are arguably more stable, versatile and
cheaper to produce, making them the current preferred choice across sensing platforms [47].
3.4.1. Aptamers
Aptamers are short ssDNA or ssRNA molecules, having a length of 25–100 bases, that
fold into stable three-dimensional conformations. Due to their structure they recognise
and bind to targets via hydrogen bonding, van der Waals forces and/or electrostatic
interactions [54,75,76]. This behaviour makes them ideal biorecognition elements for
targeting pathogens with high affinity and specificity. Compared to antibodies, aptamers
exhibit significant advantages, including lower molecular weight, easier and cheaper
production methods and good chemical stability [77–79].
In addition, another advantage of aptamers is that they can be raised against an
extensive variety of targets from small molecules to big proteins and also live cells, such
as whole bacteria, for example [80]. The general steps of SELEX are illustrated in Figure 4.
They can be briefly described as: (1) the target molecules (or cells) are incubated for a
defined period with a ssDNA library pool; (2) non-binding sequences are then rinsed
off; (3) next, bound sequences are recovered and PCR-amplified—for example, by using
fluorescein isothiocyanate-labelled sense primers and biotin-labelled antisense primers;
(4) finally, the antisense strands are removed to generate ssDNA pools for subsequent
cycles of selection. As the cycles progress, various parameters, such as incrementing the
number rinses, can be performed to increase stringency, allowing retention of aptamers
with the strongest affinity from the pool. Flow cytometry is often used to monitor the
enrichment of the selected pools by binding assays with the target, whereby selected pools
with increased fluorescence are compared to the DNA library. To increase specificity to the
target, the recovered pools obtained after some of the rounds are incubated with control
molecules/cells to filter out sequences that bind to common sites present on the target, in
addition to on the control [81,82].
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The selected aptamers are being used as biorecognition elements in sensing platforms
to detect a wide variety of pathogens in patient samples. For example, an innovative
approach was developed by Wang et al. [75] to produce an aptamer-based device for
application in bacterial infection diagnostics. The authors screened aptamers using cell-
SELEX and identified highly specific aptamers capable of recognising three nosocomial
and antibiotic-resistant bacteria, na ely E. coli, Acinetobacter baumannii and the multidrug-
resistant S. aureus. These apta ers ere further integrated into a icrofluidic syste to
for a paper-based dual-aptamer microfluidic chip. Compared with traditional laboratory
techniques, this microfluidic system exhibited many advantages, including faster detection
times, smaller size, higher specificity and multiplex capabilities.
In t r st , Savory and collaborators [83] used bacterial cell-SEL X to screen for
aptamers against Proteus mirabilis, which causes catheter-associated urinary tract infections,
in combination with in silico maturation (ISM) t improve aptamer specificity. ISM uses
a genetic l orithm to predic a tamer sequence with stronger target affinity than the
promising parent sequences rais d by cell-SELEX. This is achieved through successive
rounds of sequence scrambling and random mutati n in silico, followed by functional
screening in vitro and selection of improved aptamers. After two cycles of ISM, one
aptamer displayed a 36% hig er specifi ty value than the original sequence s lect d by
cell-SEL X [83].
ta fi i the detection of tuberculosi [84]. During the arly stages of
infection by virulent M. tuberc losis, culture filt ate p ot in 10 (CFP10) and early secreted
antig n target-6 (ESAT ) antigens are secret d and the detection of such proteins can be
used for the early and specific diagnosis of tuberculosis [85]. Therefore, Tang et al. [84]
raised aptamers against CFP10 and ESAT6 antigenic targets using SELEX. The selected
screened aptamers (CE24 and CE15) were used in an enzyme-linked oligonucleotide assay
(ELONA) to detect the proteins CFP10 and ESAT6 in serum samples of patients with active
pulmonary tuberculosis, extra-pulmonary tuberculosis and healthy donors. The results
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demonstrated a specificity and sensitivity of 94.1% and 100% (using CE24-based ELONA)
and, 94.1% and 89.6% (using CE15-based ELONA), respectively [84].
Recently, aptamers have also been conjugated with MNPs to improve diagnosis. For
example, Wang et al. [86] developed POC diagnostic systems to diagnose sepsis and
perform blood disinfection using aptamers. The commercial aptamers able to recognise
bacterial species were conjugated with iron oxide MNPs functionalised with chlorin e6
(Fe3O4-Ce6-Apt). This nano-system allowed successful diagnosis of sepsis in mouse models
caused only by S. aureus or by multiple bacterial species, namely S. aureus and E. coli, with
a detection sensitivity comparable with serological techniques and a shorter turnaround
time. Moreover, a total extracorporeal disinfection of blood was achieved due to the strong
photodynamic effect of the Fe3O4-Ce6-Apt system. Another example of Fe3O4 MNPs
functionalised with aptamers was reported by Hao et al. [87] for the specific capture of
enteropathogenic S. typhimurium. Commercially available specialised aptamer complexes
containing a sequence specific to capture S. typhimurium and a primer region used to assist
in detection were used. These primer sequences play a role in rolling circle amplification
(RCA) to produce long ssDNA with hundreds of tandem-repeat sequences [88]. Therefore,
while the bacteria are captured, simultaneously several signal probes are assembled on the
RCA products for enhanced amplification of the recognition event. This unique method
was reported to have a high selectivity for S. typhimurium, with an excellent LOD equal to
10 CFU/mL.
In addition to the abovementioned studies, there are currently many other examples of
aptamers used to identify various pathogens and their biomarkers [89–91]. Tables 2 and 3
summarise other examples of aptamers used to identify human bacterial pathogens and
viral human pathogens, respectively, for the diagnosis of infections.
Table 2. Summary of recent aptamer-based methods for the identification of bacterial pathogens.
Bacteria Target (Analyte) Detection System Refs.
Escherichia coli O157:H7 and
Salmonella typhimurium Whole bacteria
Aptamer-modified fluorescent
magnetic multifunctional nanoprobes [92]
Staphylococcus aureus and
Escherichia coli Whole bacteria
Multiplex aptamer-based
hydrogel barcodes [93,94]
Escherichia coli O157:H7 Whole bacteria
Electrochemical biosensor with
amino-functionalised metal–organic
frame integrated with aptamers
[95]





Staphylococcus aureus Enterotoxin A protein Graphene oxide-basedfluorescent bioassay [97]
Staphylococcus aureus Whole bacteria Surface-enhanced Raman spectroscopy(SERS) biosensor [98]
Campylobacter jenuni Whole bacteria N/A [77]
Streptococcus pyogenes M11 M-type serotype whole bacteria N/A [99]
Mycobacterium tuberculosis MPT64 secreted protein Enzyme linked oligonucleotide assay [100]
Methicillin-resistant
Staphylococcus aureus (MRSA) Penicillin binding protein 2a (PBP2a) Fluorometric assay [101]
Pseudomonas aeruginosa Whole bacteria Fluorometric assay [102]
N/A—Not Applicable.
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Table 3. Summary of recent aptamer-based methods for the identification of viral pathogens.
Virus Target (Analyte) Detection System Refs.
Avian influenza strain H5Nx Whole virus Sandwich-type surface plasmonresonance (SPR)-based biosensor assay [103]
Influenza A strain H3N2 Globular region of hemagglutinin Aptamer-functionalised magneticmicroparticle-based colorimetric method [104,105]
Zika Zika NS1 Protein Aptamer-Based enzyme-linkedimmunosorbent assay (ELISA) [106]
Norovirus Murine norovirus and capsids of ahuman norovirus strain GII.3 Electrochemical sensor [107]
H1N1 Inactivated H1N1 virus particles Electrochemical impedance sensor [108]
Human immuno-deficiency
virus Type 1 (HIV-1) Glycoprotein-120 (gp-120) Liquid crystal optical sensor [109,110]
Human papillomavirus (HPV) L1-major capsid protein of HPV Electrochemical impedance sensor [111,112]
SARS-CoV-2 Receptor-binding domain (RBD) ofthe spike glycoprotein N/A [113]
SARS-CoV-2 Nucleocapsid protein ELISA and a gold nanoparticleimmunochromatographic strip [114]
SARS-CoV-2 Nucleocapsid protein N/A [115]
SARS-CoV-2 Spike glycoprotein N/A [116]
Ebola Viral RNA Antiresonant reflectingoptical waveguide [117]
N/A—Not Applicable.
Despite aptamers’ numerous advantages and recognised potential, the translation of
aptamer-based products to the clinics or other markets has been slow [118,119]. Reasons
for this include the high financial investment made in the research and production of
antibodies, and the general unfamiliarity regarding aptamers and their interesting perfor-
mance [120]. In addition, although aptamers may be cheaper to produce, in general, the
affinity properties of antibodies in comparison to aptamers remain superior. Furthermore,
SELEX can be a very time-consuming process. However, their advantages together with an
increasing awareness about them could lead, in the near future, to a wider use of aptamers
in the increasingly relevant POC diagnostics and therapeutics field.
3.4.2. DNAzymes
DNAzymes, also called deoxyribozymes, are synthetic ssDNA oligonucleotides that
display catalytic activities [121]. Inspired by the existence of naturally occurring ri-
bozymes (RNAzymes), Breaker and Joyce identified, in 1994, the first DNA-like enzymes
by SELEX [122]. DNAzymes were initially produced for the detection of lead contam-
inations [123]. More recently, they have been generated to identify cancer cells [124],
pathogenic bacteria [125] and other biomarkers. For example, Zheng et al. [125] created a
sensing platform using MNPs functionalised with a fluorescently-responsive DNAzyme
for the detection of pathogenic E. coli. The E. coli-specific DNAzyme was synthesised by
template-mediated ligation and further modified with MNPs and acetylcholinesterase
(AChE) to form a complex. In the presence of bacterial lysate, the DNAzyme domain binds
to target molecules from the bacterial content, triggering a cleavage event which releases
AChE. The free AChE subsequently plays a role in enhancing the fluorescence signal of the
detection system. DNAzymes were found to bind to the target with high specificity and
sensitivity, exhibiting a LOD of 60 CFU/mL with a linear range from 102 to 107 CFU/mL.
A highly innovative system for the detection of bacteria in blood was also developed
by Kang et al. [126]. SELEX was used to identify DNAzymes with specificity to the E. coli
lysates. The construction of the DNAzyme is shown in Figure 5. The DNAzyme domain
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was enzymatically ligated with a DNA–RNA chimeric substrate. This substrate contained
a ribonucleotide cleavage site flanked by a fluorophore and a quencher. In the presence of
the target E. coli lysate, the DNAzyme binds the target molecule, changes its conformation
and cleaves the fluorophore from its quencher, generating a high fluorescence detectable
signal. During detection, DNAzyme sensors were mixed with blood constituents and then
encapsulated in hundreds of millions of picolitre droplets. These were analysed by a 3D
high-throughput particle counter to detect fluorescent particles. Using this method, E. coli
was detected in a range of very low concentrations from a single cell up to 104 cells per
mL within a span of 1.5 to 4 h. Afterwards, this biosensor was adapted for detection of
Klebsiella pneumoniae in a fluorescent paper sensor [127].
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DNAzymes were also successfully employed in a colorimetric paper sensor for the
sensitive detection of another human pathogen, Helicobacter pylori, from human stool
samples achieving a LOD of 104 CFU/mL [128]. The RNA-cleaving properties of the
DNAzyme were activated by a protein biomarker of H. pylori and the DNAzyme was
identified by an in vitro selection process similar to SELEX. The method required minimal
sample processing and was completed in a few minutes.
In relation to virus detection, Kim et al. [129] devised a fast and simple colorimetric
assay to detect the human immunodeficiency virus (HIV) from human serum using a
previously established functional DNAzyme motif generated by conventional PCR. The
key aspect is the design of the primers that target the HIV-1 gag gene and, which during
PCR amplification, insert a functional DNAzyme sequence in the PCR product. After
amplification, hemin is added to assist in the formation of a G-quadruplex structure within
the DNAzyme sensor to catalyse the oxidation of 2,2′-azino-bis(3-ethylbenzothiazoline-
6-sulfonate) (ABTS). The oxidation of ABTS yields a change from colourless to blueish
green which can be visualised and quantified. Recently, Anantharaj et al. [130]. designed a
biosensor for the detection of SARS-CoV-2 RNA using the same working principle. This
DNAzyme sensor is highly sensitive because it selectively targets the N gene of SARS-CoV-
2, which is not present in the genomes of other viruses. The LOD of the sensor was 103
copies of viral RNA. Other recent advances of G-quadruplex DNAzyme based biosensors
were revised by Xi et al. [131].
Similar to aptamers, DNAzymes exhibit remarkable selectivity to their targets and
therefore continue to find use as recognition molecules for a wide range of applications.
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3.4.3. Peptide Nucleic Acids (PNAs)
PNAs are artificial molecules composed of a polypeptide backbone with nucleic
acid bases attached as side chains. They are notable nucleic acid analogues due to their
unique physicochemical and biochemical attributes, stability and striking hybridisation
attributes [74]. Due to these characteristics, PNAs have wide application in molecular
diagnosis [132].
A paper-based colorimetric multiplex sensor using a Pyrrolidinyl PNA (acpcPNA) probe
for the detection of Middle East Respiratory Syndrome coronavirus (MERS-CoV), human
papillomavirus (HPV) and M. tuberculosis was successfully developed by Teengam et al. [133].
The probe was based on a previously described motif [134], wherein a PNA conjugated with
modified AgNPs induces aggregation of the AgNPs in the absence of complementary target
DNA. When the target DNA is present, a DNA–acpcPNA duplex is formed, originating
the dispersion of the AgNPs and a concomitant detectable colour change.
PNA Fluorescence In Situ Hybridisation (PNA-FISH) has become useful for the spe-
cific, reliable and rapid detection of human pathogens. Machado et al. [135] developed a
novel PNA-FISH method with specificity for Lactobacillus and Gardnerella vaginalis. Speci-
ficity and sensitivity of the PNA probes were 98% and 100% for Lactobacillus and G. vaginalis,
respectively. Furthermore, the probes were evaluated in samples mimicking the vaginal
microflora of patients with a bacterial vaginosis infection, to demonstrate their applicability
for diagnosis. PNA-FISH was also recently used by Rocha et al. [136] in the detection
of L. monocytogenes using a previously developed PNA probe (LmPNA1253) selected by
Almeida et al. [137] coupled with a new blocker probe. The method was able to detect
L. monocytogenes with an LOD of 0.5 CFU/mL in certain food samples.
PNA probes have also been used in the detection of clinical viruses, such as the
hepatitis C virus (HCV), which causes chronic liver disease. Ahour et al. [138] developed
an electrochemical sensor for HCV detection based on a 20-mer PNA probe that targets
a highly conserved consensus sequence present in core/E1 domain from HCV genome.
This sequence was cloned in a recombinant plasmid that was used to test the electrode.
The PNA was able to hybridise to this sequence without being necessary to denature the
plasmid. This represents an advantage because the DNA in nature is in a double-stranded
form. Therefore, this method can be used for identification of all HCV genotypes through
direct detection. For detection, a gold (Au) electrode modified with cysteine and conjugated
with the PNA probe was used. The hybridisation detection was performed by monitoring
the difference between the voltametric response of methylene blue (which serves as an
electroactive indicator) accumulated on the PNA–modified Au electrode before and after
the hybridisation event.
It can be concluded that PNAs hybridise more efficiently with complementary DNA
and RNA because they are neutral and their interactions lack charge repulsion which is
present in other nucleic acid-based probes. Therefore, they are highly useful when used
in conjunction with technologies such as FISH to create simple, rapid and highly accurate
microbial detection sensors [139]. In addition, sensors employing PNAs have also been
suggested to have great potential in the detection and diagnosis of COVID-19, and can
thus aid in curtailing its spread [140].
3.5. CRISPR-Cas
CRISPR are a family of DNA sequences originating in bacteriophages that have
previously infected prokaryotes and subsequently become incorporated into their genomes
as a defence mechanism to recognise foreign nucleic acid sequences and eliminate them
by using the endonuclease activity associated with an enzyme called Cas. Cas evolved
in prokaryotes for defence against invading viruses by cleaving their nucleic acid like a
pair of scissors [141,142]. CRISPR RNA (crRNA) guides Cas to recognise and cleave
target nucleic acids; thus, crRNA can be programmed towards any specific DNA or
RNA of interest such as pathogenic genetic material, for instance, by hybridising to a
complementary sequence [143]. In this manner, CRISPR-Cas has been repurposed as a
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gene editing tool, in disease treatment and diagnosis [144]. For diagnostic applications,
CRISPR-Cas systems have been used to sense nucleic acid-based pathogenic biomarkers
with single-base resolution.
An example of such a system is CRISPR-Cas9, which leverages its sequence-specific
nuclease activity to distinguish between viral lineages. To illustrate, a recent Zika virus
outbreak prompted Pardee et al. [145] to develop a widely regarded workflow for a portable,
low-cost colorimetric sensor which couples isothermal RNA amplification and toehold
switches on a paper-based platform. The sensor was further coupled with a CRISPR-Cas9
module that has the ability to distinguish between strains of a virus with single-base
resolution. Briefly, in the presence of the target RNA, a Cas9-mediated cleavage is triggered,
resulting in a truncated RNA product that is unable to activate the sensor toehold switch
and does not produce a colour change in the test paper. While in the presence of non-target
viral RNA, the full-length RNA product comprising the sequence to trigger the sensor
is generated, thus activating the sensor and producing a colour change on test paper.
Detection of Zika virus from monkey plasma infected with the virus was achieved in the
low femtomolar range. Additionally, Ai et al. [146] also developed a rapid assay using
CRISPR for detection of M. tuberculosis. The method combined an amplification step of
the target bacterial sequence by recombinase polymerase amplification (RPA) followed
by a Cas12a detection step. After the amplification step, the presence of target RNA
activates the Cas12a cleavage system, which in turn triggers a colour change in an ssDNA
reporter that is present. The detection system is extremely sensitive with almost single-copy
sensitivity. More recently, Kellner et al. [147] established a platform that also combines
RPA with CRISPR-Cas to detect target RNA or DNA sequences. This platform was named
SHERLOCK, which stands for specific high-sensitivity enzymatic reporter unlocking. In
addition to being portable and extremely sensitive in the detection of DNA or RNA from
real clinical samples, this platform is able to detect multiple targets through the use of a
multiplex fluorescence-based detection system.
For the detection of SARS-CoV-2, Hou et al. [148] proposed an alternative to the stan-
dard reverse transcription quantitative polymerase chain reaction (RT-qPCR) detection by
means of a rapid assay based on polymerase-mediated amplification and CRISPR/Cas13a.
Figure 6 illustrates the steps of the assay. This isothermal method is highly advantageous
because it does not require expensive and bulky thermocycler equipment and only takes
40 min. To test the novel assay, 52 RNA samples from patients with COVID-19 were
subjected to mNGS and three potential target sequences were identified. Subsequently,
CRISPR gRNAs and RPA primers were designed and screened. A primer set that targeted
open reading frame 1ab (orf1ab) displayed the best specificity and sensitivity and was used
to develop the CRISPR assay, which was based on T7 transcription and a Cas13 detection
step. To evaluate the specificity of the CRISPR assay, target viral DNA was substituted
with human DNA and a panel of bacterial and viral pathogens. None of these test samples
caused a false positive reaction. Further, the CRISPR assay demonstrated 100% sensitivity
because it was able to detect all 52 cases of COVID-19. In the future, the role of CRISPR-
associated nucleases can be expanded for direct diagnostic testing of nucleic acids due to
their exceptional single molecule sensitivity.
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have potential for application in diagnostic tools and reatments against bacterial infec-
tion [ 49–152]. For instance, Liana et al. [153] fu ctionalised MNPs with a high density
of T4 bacteriophage and subseq ently used them to capture E. coli. T4 bacteriophages
infect E. coli a d th one used in th reported study had specificity to E. coli type B (ATCC
11303) by means of their tail fibres. In addition to the density of bacteriophage loaded on
the MNPs, the authors repor ed the important effects of rypton presence in the medium
and the incuba ion temperature used to grow E. coli in the capture capabilities of the
MNP prob s. The T4 bacteriophag s were found to bind irr versibly to E. coli at 37 ◦
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, which is highly specific to P. aeruginosa, to establish acteriophage-affinity strateg
for its detection [151]. The bacteriophage tail fibres and aseplate identified and capture
P. aeruginosa onto the MBs. Subsequently, the bacteriophage replication cycle proceeded
for about 100 min after which the progenies lysed the bacteria causing the release of
intracellular ATP. A firefly luciferase-ATP bioluminescence system was used to quantify
the captured bacteria. The LOD was determined to be 2 × 102 CFU/mL and the process of
capture and detection was completed within 2 h. To estimate the suitability of this strategy
for POC diagnosis, glucose, human urine and rat plasma samples were spiked with
P. aeruginosa at various concentrations and bacteria recovery tests with the functionalised
MBs were performed. Recovery rates ranged from 77.4% to 96.9%, demonstrating good
reliability for the detection of bacteria in complex samples [151]. In an example of multiplex
detection [150], two phage RBPs, gp18 and gp109, with potential specificity to the genera
Enterococcus or Staphylococcus, respectively, were identified in silico. The RBPs were fused
with fluorescent proteins and used in spectrofluorometric assays with the target bacteria for
their multiplex detection by fluorescence. Additionally, gp18 also showed high sensitivity
to E. faecium and E. faecalis by binding to 80% and 100% of tested strains, respectively.
The exceptional specificity displayed by bacteriophages for their target render them
prime candidates for diagnostic platforms. However, more bacteriophages that target
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other dangerous pathogens need to be further discovered or engineered to build promising
diagnostic systems that can also function as therapeutics.
3.7. Molecularly Imprinted Polymers (MIPs)
Artificial material-based biorecognition elements rely on the specific morphology or
shape of the target for selective capture [11,154]. MIPs include cell imprinted polymers
(CIPs), which are the most common examples of MIPs in the context of biorecognition.
Some processes used to produce MIPs include micro-contact stamping, bacteria-mediated
lithography and colloid imprints. For example, Khan et al. [155] fabricated a MIP by
imprinting the bacterial flagella of P. mirabilis onto electropolymerised phenol. The flag-
ellar protein imprint sites have rebinding ability in the presence of a sample containing
P. mirabilis. The MIP was evaluated for biorecognition in an electrochemical biosensor to
detect P. mirabilis during a rebinding event. The sensor was found to be highly sensitive
with an LOD of 0.7 ng/mL.
There are many more examples on the use of CIP in diagnosis. For example, Golabi
et al. [156] reported an electrochemical biosensor employing CIPs that specifically recognise
S. epidermidis. The CIPs’ fabrication is based on the polymerisation of 3-aminophenylboronic
acid. The features of the imprinted surface include complementary cavities at the polymer
surface, presenting structural specificity in terms of shape and size, but also chemical speci-
ficity via diol molecules which are present on the cell walls of S. epidermidis. The sensor
response was reported as being proportional to log 103–107 CFU/mL of S. epidermidis and
was highly specific for the target strain when compared to non-target species such as E.
coli, Deinococcus proteolyticus and S. pneumoniae. Similarly, a polydopamine-based CIP was
imprinted with template E. coli O157:H7 for capturing bacteria together with a polyclonal
antibody [157]. By electro-chemiluminescent detection, a very low LOD of 8 CFU/mL
was measured. There are other successful demonstrations of bacterial biorecognition by
employing CIPs reporting high specificity and sensitivity [158,159].
CIPs are also widely applied in the detection of virus in diagnostics [160]. Furthermore,
Cai et al. [161] developed an MIP-based sensor that exhibited exceptional specificity for E7
protein derived from the HPV [162]. The MIP was built by imprinting the tips of nanotube
arrays with a polyphenol nanocoating. The coating was non-conducting and detection
was performed by electrochemical impedance spectroscopy. The high specificity of the
sensor was confirmed when another similar protein of HPV called E6 was not recognised
by the E7 MIPs. The E7 protein was recognised with sub picogram per litre sensitivity,
surpassing that achieved by conventional MIPs and comparable with nanosensors based on
biomolecular recognition with ligands. A similarly constructed MIP system was developed
by Ma et al. [163] for specific recognition of the HIV-p24 capsid protein of the HIV virus.
Detection by MIPs is label-free and can be even more affordable than ligand-based
biorecognition platforms. However, during a binding event between template and molecules,
conversion of the resulting signal by detection systems needs to be improved, in addition
to elimination of noise in the signal.
3.8. Antibiotics
Although most antibiotics lack high selectivity due to their broad-spectrum activity, in
combination with certain upgrades that provide or improve selectivity, they have proven
to be effective for biorecognition of pathogenic targets, as illustrated by the examples pre-
sented in this section [164,165]. Antibiotics are widely available, highly stable and exhibit
strong binding capabilities to bacteria, making them excellent for combinatorial strategies
in biorecognition or in pre-enrichment steps in sensing platforms [164]. However, this
approach can only be considered for bacterial species that have not developed resistance to
the antibiotic under consideration.
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3.8.1. Vancomycin
Vancomycin (Van) is a well-known broad-spectrum lycopeptide antibiotic that in-
teracts with a range of Gram-positive bacteria. Lycopeptide antibiotics are known to
bind to the D-alanyl-D-alanine (D-Ala-D-Ala) dipeptide groups present in the cell wall of
bacterial strains through hydrogen bonds [166]. Therefore, Van is popularly used in the
functionalisation of MBs as bacterial capture probes and in combination with secondary
recognition molecules to improve specificity [164]. For example, Yang et al. [167] designed
multivalent “brush-like magnetic nanoprobes” and demonstrated their potential for the
efficient enrichment of pathogens. To construct the brush-like magnetic nanoprobes, com-
mercial amino-MBs were modified with poly-L-lysine (PLL), followed by the connection
of polyethylene glycol (PEG) to the amine sites of PLL. Van was previously linked to the
carboxyl molecule of PEG. By using these nanoprobes, an enrichment efficiency greater
than 94% was achieved, and also an excellent recovery of L. monocytogenes was obtained
within 20 min, at a bacterial concentration of 102 CFU/mL. Moreover, Meng et al. [168]
synthesised similar PEGylated MNPs functionalised with Van (Van-PMs), also to capture
and enrich the virulent foodborne pathogen L. monocytogenes from spiked lettuce samples
prior to detection by PCR. The Van-PMs displayed a high capture efficiency of around
83% and 90% with LOD of 30 CFU/g and 30 CFU/mL in lettuce samples and in PBS,
respectively. All steps, including enrichment and PCR, were accomplished in 4 h.
On another study, Yang et al. [164] synthesised MBs with a size of 100 nm function-
alised with Van to capture S. aureus prior to chemiluminescent detection. To improve the
specificity of these Van-MBs to S. aureus, rabbit Ig G (IgG) tagged with ALP was used as
a second recognition molecule, because the Fc region of rabbit IgG binds to protein A in
S. aureus surface. The resulting sandwich complex of Van-MBs-S. aureus-IgG significantly
improved the specificity due to the recognition of S. aureus at two distinct sites. In addition,
it facilitated ultrasensitive chemiluminescent detection of S. aureus in a linear range of
1.2–12 × 106 CFU/mL and with a very low LOD (3.3 CFU/mL). The entire process was
completed in 75 min.
More recently, Wang et al. [169], developed an efficient SERS biosensor that combined
Van-modified Fe3O4 AgNPs and gold and silver (Au-Ag) NPs for enrichment and sensitive
and specific detection of bacteria. The high-performance Van-Fe3O4@Ag MNPs served as
effective capture probes for Gram-positive bacteria such as E. coli, S. aureus and methicillin-
resistant Staphylococcus aureus (MRSA), achieving a LOD of 5 × 102 cells/mL. Then, the
plasmonic Au-Ag NPs were used as secondary NPs to increase the detection sensitivity.
3.8.2. Amoxicillin
Some bacteria possess so-called penicillin binding proteins (PBPs) which generate
β-lactamase enzymes to resist β-lactam producing antibiotics such as amoxicillin and
penicillin by breaking the lactam amide bond. Due to this interaction, the β-lactam in
amoxicillin has selective affinity to PBPs present on the bacterial cell membrane [170].
Based on this chemical interaction, Hasan et al. [171] synthesised an effective enrichment
probe against S. aureus and E. coli by modifying MNPs with 3-aminopropyltriethoxysilane
and amoxicillin to target PBPs. The modified MNPs successfully captured bacteria forming
aggregates that are then separated using an external magnet. MALDI-TOF was used to
confirm the interaction between the amoxicillin and bacterial PBPs. The LOD for S. aureus
and E. coli was in the range of 103–104 CFU/mL using MALDI-TOF after 5 min incubation
with amoxicillin functionalised MNPs.
3.8.3. Ampicillin
Ampicillin has all the stated advantages of antibiotics for use in biorecognition. It
is widely available, bringing down costs, and has broad-spectrum high-affinity binding
properties for bacteria. These strong affinity properties of ampicillin and the specificity
of antibodies were combined to design a LFA for detection of Salmonella enteritidis [165].
Ampicillin coated on MNPs facilitated the initial enrichment of S. enteritidis from spiked
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food samples by capture and magnetic separation. Subsequently, the enriched sample was
applied to the LFA. The anti-S. enteritidis mAB with high specificity towards S. enteritidis
dispensed on the LFA functioned as a specific enrichment agent, forming a sandwich
complex with the ampicillin-MNPs. The colour change was detected by the naked eye at
an LOD of 102–103 CFU/mL.
3.8.4. Neomycin
Neomycin is an aminoglycoside broad spectrum oligosaccharide antibiotic that tar-
gets the 30S ribosomal subunit and interferes with decoding and translocation, which,
consequently, inhibits protein synthesis in bacteria [172]. Zhang et al. [173] developed lipid
conjugated neomycin-based probes that selectively identify and label antibiotic-resistant
bacteria simultaneously without disrupting host immune cells. In addition, this probe has
theranostic abilities, such as the presence of neomycin, which inactivates the bacteria in
addition to detection. This is useful because the probe can have therapeutic and diagnostic
applications [10]. The lipidated probes exhibited highly specific and strong fluorescent
signals against MRSA and an increased inhibition effect compared to probes with only
neomycin. This increased specificity and decreased bacterial resistance is related to lipid
chains being able to increase the membrane permeability to the antibiotic. Therefore, this
strategy has the potential to detect bacterial infections with high selectivity and sensitivity,
and enhance the antibacterial effect of antibiotics without harm to host cells.
Clearly, a number of antibiotics have been tested for their potential as capture probes
and, in combination with selective ligands, can be very effective for bacterial identification.
3.9. Chemical Compounds
In addition to the classes of biorecognition elements exhaustively discussed above,
various molecules not covered by these classes also exhibit affinity and selectivity for
pathogens and can be exploited for use in sensing platforms. In one such example, Pang
et al. [174] designed a platform partly composed of maltohexaose-decorated cholesterol
that is able to target bacteria both in vitro and in vivo through a bacteria-specific mal-
todextrin transporter pathway. They investigated the theranostic capabilities of this smart
nanoliposome-based platform (MLP18) for targeting of multi-drug resistant strains of
MRSA and β-lactamase E. coli in different mouse models and subsequent delivery of pur-
purin 18 (P18), a sonosensitiser for sonodynamic therapy. After injection in a mouse-model,
the MLP18 selectively directs P18 to the bacterial infection site. Fluorescence imaging
showed that the MLP18 produced a specific fluorescence signal at the site of infection
that remained for 24 h post-injection. At the site of sterile inflammation only a negligible
fluorescence signal was detected, demonstrating the bacterial-targeting abilities of MLP18.
Moreover, Fu et al. [175] investigated the considerable potential of chemical ligand
discovery from natural sources by the coupling of affinity MS and metabolomic approaches.
They identified two ligands, 18β-glycyrrhetinic acid and licochalcone A derived from
liquorice root used in traditional Chinese medicine which were able to bind and dis-
rupt the nucleoprotein of EBV and Marburg virus. Ligand binding assays and various
biophysical analyses were used to evaluate the interactions of the ligands with the bacte-
rial nucleoproteins.
During infection, pathogens interact with host tissue and some of these interactions are
specific, such as when pathogens bind to specific host cell membrane proteins. For example,
human extracellular matrix proteins, such as collagen and fibronectin, are known receptors
for outer membrane protein adhesins present on various microbial pathogens during the
initial stages of infection [176]. These interactions can be exploited by coating collagen or
fibronectin on MBs, for example, and using them to capture and detect pathogens using
sensing platforms.
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4. Future Perspectives
A paradigm shift is taking place in the way infectious diseases, predominantly
caused by pathogenic bacteria and viruses, are being diagnosed. However, even though
highly technological methods that can highly sensitively identify pathogens from samples
emerged a few decades ago, this has not been translated into a faster, more efficient and
accurate diagnosis for most people suffering with various infections due to their inac-
cessibility. As discussed, it is evident that diagnostics in the form of simple POC tests,
biosensors and kits are the future and can greatly improve outcomes for patients due to a
timely diagnosis. Development of workflows to detect the myriad pathogens is underway
and is dominated by various sensing platforms. In this review, the latest biorecognition
elements in workflows and detection systems are categorised and a number of recent
application examples for each are elucidated. The biorecognition elements that hold the
greatest potential for incorporation into POC diagnostics are the nucleic acid derivatives, if
they can equal antibodies in performance parameters. The incorporation of such elements
can drive down the cost of biosensors. Antibody-based sensors will continue to be popular
but their market share may shrink. Alternatively, CRISPR technology has an emerging
potential for diagnostics among all the biorecognition elements herein discussed due to
their impressive sensitivity. However, extensive research is needed for each infectious
disease to choose the right combination of Cas enzyme and to design the best system.
Nevertheless, there are some bottlenecks in the translation of sensing platforms com-
prising these biorecognition elements from bench-top to clinical. A vast array of develop-
ment in the field is available, although not well organised. There is no standard method to
determine which platforms have the potential to achieve commercial development and
need more funding, for instance. Furthermore, biorecognition elements need to be subject
to some kind of standardisation procedures, in addition to parameters related to their
targets, such as LOD values. Collaboration between academia, clinical practitioners and
industries that can invest in the further development of POC sensing platforms is critical,
followed by consideration of regulatory clearance and introduction to commercial markets.
5. Conclusions
In conclusion, based on the evidence presented in this review, antibodies currently
remain the biorecognition element of choice, but alternatives, especially in the form of
nucleic acid derivatives, are being sought.
Antibodies are still dominantly used in commercial immunoassays and immunosen-
sors, and are at various stages of research. This is due to their ability to provide a combina-
tion of strong target affinity and exceptional selectivity. Furthermore, due to their extensive
use over many decades, the field of antibody selection is well developed with a vast num-
ber of molecules available and well characterised for selection based on the envisaged
application. However, alternatives are increasingly being sought due to their disadvan-
tages, including a cumbersome development and selection process that is expensive, in
addition to their inherent instability, which can make them difficult to incorporate in sensor
kits. The advantages and disadvantages of using enzymes as biorecognition elements are
similar to those of antibodies. Due to their natural origin, they display superior affinity
properties to targets, but they also suffer from instability issues, and are difficult to isolate
and process in a laboratory environment. Possibly due to this issue, the implementation of
enzymes as biorecognition elements for diagnostic applications is still limited and needs
further development.
As mentioned, the main alternatives to antibodies being studied are derivatives of
nucleic acids such as aptamers, PNAs, DNAzymes and antibody-derived fragments. The
main advantage of those molecules is that they can be developed much more cheaply than
antibodies. In some instances, they have demonstrated target affinity comparable with
their antibody counterparts while exhibiting excellent stability and reproducibility, which
is a vital requirement for POC diagnostics. They are also versatile enough to be combined
with most POC sensor detection platforms, including electrochemical, optical, colorimetric
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and LFA. Their main disadvantage is that they require a selection process that is time-
consuming and sometimes difficult to perform. However, as illustrated in this review, there
are numerous excellent examples of nucleic acid derivative-based biorecognition elements
in sensing platforms, which will certainly translate to their extensive application in POC
sensors in the near future.
Classes of compounds and molecules such as antibiotics and peptides, which were
traditionally used for anti-infective and therapeutic purposes, have seen their broad-
spectrum activity against pathogens re-purposed for pathogen identification in diagnostics.
Due to their wide range, they are usually used for pre-enrichment or combined with other
biorecognition elements to enhance the sensitivity of the sensor. A huge number of AMPs
are under scrutiny; however, their emerging disadvantage is the lack of selectivity.
Bacteriophages present excellent selectivity due to their innate targeting function,
which is similar to that of antibodies. Development of bacteriophage-based sensing plat-
forms is in a nascent stage compared to the other biorecognition elements, but their high
target specificity makes them promising candidates for biorecognition.
MIPs have been included in this review due to their importance and demonstrated
capabilities in pathogen-sensing platforms, although ligand molecules are not usually used
for biorecognition in these cases. Their advantages include lower production cost compared
to antibodies, high batch-to-batch reproducibility, and chemical and mechanical robustness,
and do not involve animals’ sacrifice. MIPs can be extremely versatile because almost any
target can be imprinted for their detection and have great potential in sensing platforms.
CRISPR-Cas technology, although still emerging in the diagnostic landscape, has al-
ready shown immense potential with platforms such as SHERLOCK-enabled multiplexed
and ultra-sensitive detection of DNA or RNA from clinical samples. The main advantage
of CRISPR is that its single-base resolution selectivity is unmatched by any other biorecog-
nition element. The nature of the technology enables it to be leveraged in POC diagnostic
sensing platforms. Finally, chemical compounds such as metabolites, polysaccharides and
several other chemicals are useful for targeting specific pathogenic targets for which they
have a known affinity interaction. In conclusion, depending on the application, one or a
combination of more suitable biorecognition element(s) investigated in this review can
provide high performance biorecognition capabilities in POC diagnostics.
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